References
Fong Y, Fortner J, Sun RL, Brennan MF, Blumgart LH. Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer: analysis of 1001 consecutive cases. Ann Surg. 1999;230(3):309–18; discussion 318–321.
Brudvik KW, Jones RP, Giuliante F, et al. RAS mutation clinical risk score to predict survival after resection of colorectal liver metastases. Ann Surg. 2019;269(1):120–6.
Kopetz S, Grothey A, Yaeger R, et al. Encorafenib, binimetinib, and cetuximab in BRAF V600E-mutated colorectal cancer. N Engl J Med. 2019;381(17):1632–43.
Kobayashi S, Takahashi S, Takahashi N, et al. Survival outcomes of resected BRAF V600E mutant colorectal liver metastases -A multicenter retrospective cohort study in Japan. Ann Surg Oncol. 2020. https://doi.org/10.1245/s10434-020-08817-8.
Cremolini C, Loupakis F, Antoniotti C, et al. FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE study. Lancet Oncol. 2015;16(13):1306–15.
Funding
This study received financial support from the National Cancer Center Research Development Fund (Research no. 30-A-8; principal investigator: Shinichiro Takahashi).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Disclosure
Hiroya Taniguchi received honoraria from Takeda, Chugai, and Taiho pharmaceutical companies. Takayuki Yoshino received research funding from Novartis Pharma K.K., MSD.K.K., Sumitomo Dainippon Pharma Co., Ltd., CHUGAI PHARMACEUTICAL CO., LTD., Sanofi K.K., DAIICHI SANKYO COMPANY, LIMITED, PAREXEL International Inc., ONO PHARMACEUTICAL CO., LTD., and GlaxoSmithKline K.K.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Kobayashi, S., Takahashi, S., Yoshino, T. et al. ASO Author Reflections: The Moment That BRAF V600E Mutation Starts Evolving into “Precision Oncosurgery” in Colorectal Liver Metastases. Ann Surg Oncol 27, 3316–3317 (2020). https://doi.org/10.1245/s10434-020-08818-7
Received:
Published:
Issue Date:
DOI: https://doi.org/10.1245/s10434-020-08818-7